HPLC analysis of N-glycans quantified levels of the biantennary glycan (A2) in plasma proteins of 924 individuals. Subsequent genome-wide association study (GWAS) using 317,503 single nucleotide polymorphysms (SNP) identified two genetic loci influencing variation in A2: FUT 8 and ESR2. We demonstrate that human glycans are amenable to GWAS and their genetic regulation shows sex-specific effects with FUT 8 variants explaining 17.3% of the variance in pre-menopausal women, while ESR2 variants explained 6.0% of the variance in post-menopausal women. 
Main text
Glycosylation, which involves the addition of sugar chains to proteins and lipids, is the most complex and abundant post-translational modification (1) . This process is not directly template driven and gives rise to the extensive complexity of the glycoproteome, estimated to be several orders of magnitude more complex than the proteome itself (2) . In eukaryotes, glycosylation occurs through 11 biosynthetic pathways (3) . One of these pathways is Nglycosylation, which occurs when a block of 14 sugars (the dolichol phosphate precursor) is transferred co-translationally to specific Asn residues in newly synthesized polypeptides in the endoplasmic reticulum. The resulting N-glycans are subjected to extensive modification as the glycoproteins mature and move via the Golgi complex to their intra-and extra-cellular destinations (4) . N-glycosylation is essential for multicellular life and its complete absence is embryonically lethal (5) . Genetic defects that affect protein glycosylation through biosynthetic or degradation pathways are relevant to human health and are at the root of at least 30 human diseases (2, 6) . A surprisingly high proportion of disease-causing mis-sense mutations result in gains of glycosylation sites (7, 8) . Population variability in terminal glycans is also common (e.g., ABO blood groups) and contributes to the protein heterogeneity that can be advantageous for evading pathogens and adapting to a changing environments (9) . However, due to experimental limitations in quantifying glycans in complex biological samples, understanding of the genetic regulation of glycosylation is still very limited (2) .
Until recently, detailed quantitative analysis of total plasma glycans was generally performed on a limited number of samples due to the technological challenges (10) . However, using a newly developed 96 well plate platform we have demonstrated that human plasma N-glycans can be separated into chromatographic peaks and reliably quantified using high-performance liquid chromatography (HPLC) (11, 12 ). This represents a major technological advance, which was required to investigate the genetic regulation and biological role of glycan structures and for bringing glycomics into line with genomics, proteomics and metabolomics. We analysed the distribution of plasma glycans in a sample of 924 individuals recruited as part of a larger study of several hundred disease-related quantitative traits in a Croatian isolated population (12, 13) . Firstly, we found unusual biological variability at the population level with the median ratio of minimal to maximal values of 6.2 (from data on 33 chromatographic classes of N glycans (12) ) and significant age-and gender-specific effects were also present. Heritability estimates for individual glycans varied widely, ranging from very low to very high. Environmental determinants were also detected, including diet and smoking (12) .
In parallel to these developments in high-throughput glycome analysis, high-throughput genome analysis has brought unprecedented successes in gene identification in recent years (14) . Genome-wide association studies are now established as a reliable and powerful tool to identify genetic variants underlying biological variation in quantitative traits and complex human diseases (15) . This paper represents the first attempt to investigate whether a GWAS approach can be applied to the study of genetic regulation of individual glycan in human plasma quantified by HPLC.
In the HPLC method, only one glycan structure (A2, GlcNAc2Man3GlcNAc2) was individually quantified, while all others were clustered into groups that share similar structures and require further enzymatic treatment to separate them (12) . Glycan A2 mostly originates from immunoglobulin G (IgG) and differences in glycans attached to IgG glycoforms potentially affect disease susceptibility through effects on immune function (16, 17) . Glycan A2 showed substantial heritability in our study sample of 924 individuals residing in Croatian island isolates (h2=0.48; SE(h2) = 0.11). After initial HPLC quantification of glycan A2 we performed sialidase digestion to improve measurement precision. Trait concentrations were then log 10 -transformed, standardized by sex and age and z-transformed prior to genetic analysis. We successfully performed a genome-wide association study using 317,503 single nucleotide polymorphisms (SNPs) in 924 individuals from the Croatian isolate (12) . An association was considered statistically significant at the genome-wide level if the p-value for an individual SNP was less that 1.7x10 -7 (based on Bonferroni correction to account for multiple testing). For details of the methods used see Supplementary Methods.
The genome-wide association study identified a "peak" on chromosome 14 (Figure 1 ), which included 6 single nucleotide polymorphisms (SNPs) showing association with glycan A2 and genome-wide significance. The most significant association was found with single nucleotide polymorphism rs7161123 located in intron 2 of the gene fucosyltransferase 8 (FUT8) (p=1.09 x 10 -8 ). This implies that fucosyltransferase 8 is the key regulator of glycan A2 concentration in human plasma. Allele A of this SNP alone explained 3.93% of the variance of glycan A2 (after adjustment for age and sex). This association is highly biologically plausible because glycan A2 is a known substrate for FUT8 (18) . In addition to FUT8, there are three other enzymes that are directly involved in the metabolism of A2 glycan and which could potentially affect its plasma concentration (18): (i) α-1,6-mannosyl-glycoprotein 2-β-Nacetylglucosaminyltransferase, an enzyme that adds N-acetylglucosamine to mannoses and creates glycan A2; (ii) β-1,4-mannosyl-glycoprotein β1,4-N-acetylglucosaminyltransferase III, an enzyme that adds bisecting N-acetylglucosamine and decreases A2 by converting it to A2B; (iii) β-1,4-galactosyltransferase 1, an enzyme that adds galactose to Nacetylglucosamines and converts glycan A2 to A2G and A2G2 structures. We were not able to identify any SNPs in the genes encoding those enzymes that significantly affect glycan A2 concentrations in our study sample.
More detailed analyses provided further insights into the genetic regulation of glycan A2. In a genome-wide association study of glycan A2 levels prior to desialylation (sialidase digestion) of all glycans the peak on chromosome 14 was still apparent, but it barely reached genomewide statistical significance. This implies that sialidase digestion improved the detectability of true genetic effects on a N-glycan and should be performed prior to HILIC HPLC analysis in genetic association studies. In addition, it was noted that the entire peak on Chr 14 can be explained by independent effects of only 2 SNPs: rs7161123 (in gene FUT8) and rs3020450, which also showed a strong association with glycan A2 (p=6.56 x 10 -6 ) ( Table 1) . The latter SNP is located in a different gene (estrogen receptor beta -ESR2) and acts independently and additively with FUT8 to regulate levels of glycan A2. The independence between the action of two SNPs is illustrated by physical separation of the peaks on chromosome 14 on a higher resolution (r 2 = 4.68x10 -04 ) (Supplementary figure 1) and the p-value for the effect of the interaction of the two SNPs on A2 glycan level was not statistically significant. Analysis of the combined effects of rs7161123 in FUT8 and rs3020450 in ESR2 on glycan A2 levels through multi-locus analysis showed p-value of 1.36 x 10 -12 for the association of the haplotype with the trait in an additive model, with a combined effect of the two SNPs on the variance of glycan A2 (adjusted for age and sex) of 6.66%. This increased to 10.84% when the analysis was performed separately in females and decreased to 2.67% when performed only in males (Supplementary table 1) .
Further analyses provided novel insights into the nature of genetic regulation of N-glycans in human plasma. A separate genome-wide association study by gender was performed, in which the values of glycan A2 were adjusted for age only. In this study conducted in 536 females rs7161123 in FUT8 was again the SNP most significantly associated with glycan A2 (p=1.15 x 10 -9 ). An analysis in 388 males did not show any significant associations with glycan A2. The effect size of rs7161123 allele A in FUT8 in females was large, explaining 7.59% of ageadjusted trait variance (in comparison to 0.57% in males only). A similar study of rs3020450 in the ESR2 gene (A allele tested) showed the effect of SNP on the variance of the trait of 2.73% (3.25% in females and 2.10% in males). Thus, the association with FUT8 appears to be restricted to females, while ESR2 affects glycan A2 in both sexes.
The breakdown of females into premenopausal (N=166) and postmenopausal groups (N=352) and further association analysis showed that FUT8 rs7161123 explains 17.31% of the trait variance (adjusted for age) in premenopausal women and 3.61% in postmenopausal women. In contrast, ESR2 rs3020450 explained 0.51% of A2 glycan in premenopausal and 5.96% in postmenopausal women. This is the first study of human N-glycan concentrations, measured as a quantitative trait, using a genome-wide association study. Recent technological advances in high-throughput glycome analyses combined with high-throughput genomics and mass spectrometry of proteins and lipids are set to reveal complex interactions between genes, proteins, lipids and glycans and unknown steps in metabolic pathways. This first insight into genetic regulation of plasma levels of an individual glycan (A2) showed strong sex-specific effects, differences in pre-and post-menopausal life and multi-locus effects, similar to many other quantitatively varying biological traits (19, 20) . It also showed that desialylation of glycan A2 before HPLC analysis reduced the measurement "noise" and so increased the power of the study to detect genetic effects. Although glycosylation is the most complex and abundant posttranslational modification, the importance of complex oligosaccharide structures attached to proteins for human health is only beginning to be appreciated (17) . This is not surprising, since sequencing or synthesizing of branched sugar structures is significantly more challenging than the analysis of linear DNA and protein sequences (11) . However, this study is encouraging because it shows that these difficulties can be overcome. In the next few years, we should expect new and exciting discoveries on the role of glycan structures in human biology, health and disease.
Supplementary Methods
Human samples. This study was based on samples from respondents who were residents of the Croatian island of Vis and who were recruited within a larger genetic epidemiology program which seeks to investigate genetic variability influencing common complex diseases and disease-related traits in genetically isolated populations (21) . The island of Vis is one of the Dalmatian islands that has been moderately isolated throughout history. The sampling framework was based on the voting register which was used to send postal invitations to all adult inhabitants (over 18 years of age). The sample for this study consisted of a total of 1008 individuals aged 18-93 years (median age 56, interquartile range 24 years). There were 415 men (41.2%) and 593 women (58.8%). Genealogical records were reconstructed based on the Church Parish records and information provided by the respondents, and then checked against genetic data on allele sharing between relatives as a quality control measure to exclude data errors. The sample contained a total of 809 genealogical relationships (including 205 parentchild, 123 sibling, and 481 other relationships). Blood samples were centrifuged at the time of collection and EDTA plasma aliquots stored at -70 °C until analysis. This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. All respondents signed informed consent before participating in the study and the study was approved by the appropriate Ethics Board of the University of Zagreb Medical School.
Glycan release and labeling. The N-glycans from plasma sample (5 μl) proteins were released and labeled with 2-aminobenzamide (LudgerTag 2-AB labeling kit Ludger Ltd., Abingdon, UK) as described previously (22) . Labeled glycans were dried in a vacuum centrifuge and redissolved in known volume of water for further analysis.
Sialidase digestion. Aliquots of the 2-AB-labeled glycan pool were dried down in 200-μl microcentrifuge tubes. To these, the following was added: 1 μl of 500 mM sodium acetate incubation buffer (pH 5.5), 1 μl (0.005 units) of ABS, Arthrobacter ureafaciens sialidase (releases α2-3, 6, 8 sialic acid, Prozyme) and H 2 O to make up to 10 μl. This was incubated overnight (16-18 h) at 37 °C and then passed through a Micropure-EZ enzyme remover (Millipore, Billerica, MA, USA) before applying to the HPLC.
Hydrophilic interaction high performance liquid chromatography (HILIC).
Released glycans were subjected to hydrophilic interaction high performance liquid chromatography (HILIC) on a 250 x 4.6 mm i.d. 5μm particle packed TSKgel Amide 80 column (Anachem, Luton, UK) at 30°C with 50 mM formic acid adjusted to pH 4.4 with ammonia solution as solvent A and acetonitrile as solvent B. 60 min runs were on a 2795 Alliance separations module (Waters, Milford, MA). HPLCs were equipped with a Waters temperature control module and a Waters 2475 fluorescence detector set with excitation and emission wavelengths of 330 and 420 nm, respectively. The system was calibrated using an external standard of hydrolyzed and 2-AB-labeled glucose oligomers from which the retention times for the individual glycans were converted to glucose units (GU) (23) . Glycans were analyzed on the basis of their elution positions and measured in glucose units then compared to reference values in the "GlycoBase" database (available at: http:// glycobase.nibrt.ie) for structure assignment (24) . . Genotyping. A genome-wide association scan using 317,503 SNPs (Human Hap300, Illumina) was initially carried out in 991 Croatian individuals and scored using the BeadStudio software v.3 (Illumina). We removed a total of 7,096 SNPs that had <95% genotyping call rates, 1,289 that had a minor allele frequency <2% 113 that were out of Hardy-Weinburg equilibrium (p<1 x 10 -10 ) and 9 X-linked markers that were likely to be autosomal, leaving 308,996 SNPs in the analyses.
Genome-wide association analysis. We removed 60 individuals who had low call rates (<97%), one individual with too high IBS (a known twin) and 6 individuals with sex discrepancies, leaving 924 individuals in this analysis. Genome-wide associations between glycan A2 phenotype and single nucleotide polymorphic (SNP) markers were analysed using the "mmscore" function of the GenABEL package for R statistical software (http://mga.bionet.nsc.ru/nlru/GenABEL), using an additive model. This score test for family based association (25) takes into account pedigree structure and allowed unbiased estimations of SNP allelic effect relatedness between examinees. The relationship matrix used in this analysis was generated by the "ibs" function of GenABEL which used IBS genotype sharing to determine the realised pairwise kinship coefficient similarly to the PLINK "genome" function. All identified SNPs that reached significance or seemed to be suggestive of significance were visualised using HaploView software (http://www.broad.mit.edu/mpg/haploview/). The percentage of the variance explained by one or 2 SNPs was calculated using the "polygenic" function of the "GenABEL" package. Haplotype analysis was performed using the haplo.stat package for R (http://cran.rproject.org/web/packages/haplo.stats/index.html).
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Supplementary figure 1.
The independence between the action of rs7161123 in FUT8 and rs3020450 in ESR2 on glycan A2 levels is shown by physical separation of the peaks on chromosome 14 on a higher resolution. Correlation (r2) between the two SNPs is only 4.68x10 -04 . Analysis of the combined effects of rs7161123 in FUT8 and rs3020450 in ESR2 on glycan A2 levels shows strong haplotype effects and explains up to 10% of the trait variance.
